Cyclacel Pharmaceuticals to Webcast Institutional Investor and Analyst Presentation on Clinical Development Plan of Sapacitabine for MDS
May 28 2014
BERKELEY HEIGHTS, N.J., May 28, 2014 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it will webcast an invitation-only institutional investor and analyst presentation from 6:30 p.m. to 8 p.m. CDT, Saturday, May 31, in Chicago during the 2014 ASCO Annual Meeting.
The program will feature remarks by Hagop Kantarjian, M.D., Chief, Department of Leukemia, The University of Texas MD Anderson Cancer Center, a key opinion leader in the field of myelodysplastic syndromes (MDS). The speaker will provide a treating physician's perspective of intermediate-2 and high-risk MDS after treatment failure of front-line agents and an overview of the treatment landscape. Judy Chiao, M.D., Cyclacel's Vice President, Clinical Development and Regulatory Affairs, will review available clinical data with oral sapacitabine in this population and discuss plans for a randomized controlled trial of sapacitabine for the indication of intermediate-2 and high-risk MDS after treatment failure of hypomethylating agents.
The event will be webcast live at 6:30 p.m. CDT. To access the webcast please visit Cyclacel's website at www.cyclacel.com, under the Investors & Media section, approximately 10 minutes prior to the presentation in order to register and download the necessary software. An archived recording will be available on the company's website following the presentation.
The event is not an official event of the 2014 ASCO Annual Meeting and it is not sponsored or endorsed by ASCO or Conquer Cancer Foundation.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer and in particular those carrying gBRCA mutations. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.
© Copyright 2014 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
CONTACT: Contacts for Cyclacel Pharmaceuticals, Inc. Company: Paul McBarron (908) 517-7330, email@example.com Investor Relations: Russo Partners LLC, Robert Flamm (212) 845-4226, firstname.lastname@example.org